Search

Your search keyword '"Ragnhammar P"' showing total 185 results
Start Over Author "Ragnhammar P"
185 results on '"Ragnhammar P"'

26. The Swedish Council on Technology Assessment in Health Care (SBU)systematic overview of chemotherapy effects in some major tumourtypes--summary and conclusions.

Author

Glimelius, B, Bergh, J, Brandt, L, Brorsson, B, Gunnars, B, Hafstrom, L, Haglund, U, Hogberg, T, Janunger, KG, Jonsson, PE, Karlsson, G, Kimby, E, Lamnevik, G, Nilsson, S, Permert, J, Ragnhammar, P, Sorenson, S, Nygren, P, Glimelius, B, Bergh, J, Brandt, L, Brorsson, B, Gunnars, B, Hafstrom, L, Haglund, U, Hogberg, T, Janunger, KG, Jonsson, PE, Karlsson, G, Kimby, E, Lamnevik, G, Nilsson, S, Permert, J, Ragnhammar, P, Sorenson, S, and Nygren, P

Published
2001

31. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation.

Author

Ullenhag, G, Bird, C, Ragnhammar, P, Frödin, J E, Strigård, Karin, Olsterborg, A, Thorpe, R, Mellstedt, H, Wadhwa, M, Ullenhag, G, Bird, C, Ragnhammar, P, Frödin, J E, Strigård, Karin, Olsterborg, A, Thorpe, R, Mellstedt, H, and Wadhwa, M

Abstract

We have assessed the immunogenicity profile of GM-CSF in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy. Metastatic CRC patients received a colon carcinoma-reactive antibody and high doses of GM-CSF (425--500 microg/day for 10 days), while other CRC patients and those with myeloma received low doses of GM-CSF (75--80 microg/day for 4 days) as an adjuvant along with appropriate tumor antigens. We found that 55% of the patients (11/20) given high doses of GM-CSF developed GM-CSF-reactive antibodies in comparison with an incidence of only 16% (4/25) in patients given low doses of GM-CSF. None of the patients developed neutralizing antibodies and so the biological effects of GM-CSF were not compromised. A majority of patients (80%) (36/45) also developed antibodies to E. coli proteins that were present as trace contaminants in the GM-CSF product. Treatment with recombinant GM-CSF products, therefore, may induce antibodies against this cytokine depending on the regimen and the amounts used. In this study, multiple immunizations with low doses of GM-CSF was associated with a low incidence of GM-CSF antibodies, which did not neutralize the effect of the cytokine. This therapeutic strategy was effective in inducing adjuvant-type effects and needs to be explored in further clinical trials with this cytokine.

Published
2001
Full Text
View/download PDF

38. Colorectal cancer

Author

Mellstedt, H, Fagerberg, J, Frodin, JE, Liljefors, M, Ragnhammar, P, Mellstedt, H, Fagerberg, J, Frodin, JE, Liljefors, M, and Ragnhammar, P

Published
1996

49. Therapy of Colorectal Carcinoma with Monoclonal Antibodies (MAb17-1A) Alone and in Combination with Granulocyte Monocyte-Colony Stimulating Factor (GM-CSF)

Author

Mellstedt, H., primary, Früdin, J.-E., additional, Ragnhammar, P., additional, Masucci, G., additional, Ljungberg, A., additional, Hjelm, A.-L., additional, Fagerberg, J., additional, Lindemalm, C., additional, Österborg, A., additional, Wersäll, P., additional, Christensson, B., additional, Shetye, J., additional, Biberfeld, P., additional, Makower, J., additional, Cedermark, B., additional, Erwald, R., additional, Nathansson, J., additional, Magnusson, I., additional, and Rrieger, Å., additional

Published
1991
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results